HOME   Cart(3)   Quotation   About-Us Policy PDFs Standard-List
www.ChineseStandard.net Database: 189759 (19 Oct 2025)

YY/T 1888-2023 English PDF

US$379.00 · In stock
Delivery: <= 4 days. True-PDF full-copy in English will be manually translated and delivered via email.
YY/T 1888-2023: Calibration Specification for Half-value Layer Meters of(20~150)kV X-ray beam
Status: Valid
Standard IDContents [version]USDSTEP2[PDF] delivered inStandard Title (Description)StatusPDF
YY/T 1888-2023English379 Add to Cart 4 days [Need to translate] Calibration Specification for Half-value Layer Meters of(20~150)kV X-ray beam Valid YY/T 1888-2023

PDF similar to YY/T 1888-2023


Standard similar to YY/T 1888-2023

YY/T 1897   YY/T 1843   YY/T 1837   

Basic data

Standard ID YY/T 1888-2023 (YY/T1888-2023)
Description (Translated English) Calibration Specification for Half-value Layer Meters of(20~150)kV X-ray beam
Sector / Industry Medical Device & Pharmaceutical Industry Standard (Recommended)
Classification of Chinese Standard C30
Classification of International Standard 11.040.30
Word Count Estimation 18,171
Date of Issue 2023-01-18
Date of Implementation 2023-07-20
Issuing agency(ies) State Drug Administration
Summary This standard specifies the quality control, technical requirements, test methods, stability, biological evaluation, packaging, transportation and storage of recombinant humanized collagen. This standard applies to the quality control of recombinant humanized collagen that does not contain the amino acid sequence of non-human collagen as raw materials for medical devices.

YY/T 1888-2023: Calibration Specification for Half-value Layer Meters of(20~150)kV X-ray beam

---This is a DRAFT version for illustration, not a final translation. Full copy of true-PDF in English version (including equations, symbols, images, flow-chart, tables, and figures etc.) will be manually/carefully translated upon your order.
ICS 11.040.30 CCSC30 Pharmaceutical Industry Standard of the People's Republic of China Recombinant Humanized Collagen Released on 2023-01-18 2023-07-20 Implementation Released by the State Drug Administration

foreword

This document is in accordance with the provisions of GB/T 1.1-2020 "Guidelines for Standardization Work Part 1.Structure and Drafting Rules for Standardization Documents" drafting. Please note that some contents of this document may refer to patents. Publishing of this document The Agency assumes no responsibility for identifying patents. This document is proposed by the State Drug Administration. This document is under the jurisdiction of the Medical Device Technology Evaluation Center of the State Food and Drug Administration. This document was drafted by. Fudan University, Sichuan University, Institute of Biophysics, Chinese Academy of Sciences, Second Affiliated Hospital of Chongqing Medical University, Sichuan Medical Device Biomaterials and Products Inspection Center Co., Ltd. (Sichuan Medical Devices Biomaterials and Products Inspection Center), Shaanxi Provincial Food Institute for Drug Control, Shandong Institute for Medical Device and Drug Packaging Inspection, Sichuan Institute for Drug Control (Sichuan Medical Device Testing Center), Shanxi Jinbo Biomedicine Co., Ltd., Jiangsu Chuangjian Medical Technology Co., Ltd., Shanghai Zhongke New Life Biology Co., Ltd. Technology Co., Ltd. The main drafters of this document. Lu Lu, Wang Yunbing, Zhu Yun, Yang Li, Lin Hai, Dong Xiaojing, Liang Jie, Cai Hu, Zhang Min, Liu Xinglan, Wang Jian, Li Haihang, Ruan Hongqiang, Jiang Shibo, Deng Xiang, Wang Changhe, Hou Li, Zhao Daiguo, Yu Yufeng, Fan Xiaoju, Liu Jingtang, Hua Chen. Recombinant Humanized Collagen

1 Scope

This document specifies the quality control, technical requirements, test methods, stability, biological evaluation and packaging of recombinant humanized collagen. Packing, transportation and storage etc. This document applies to the quality of recombinant humanized collagen that does not contain the amino acid sequence of non-human collagen as a raw material for medical devices control. NOTE. The samples validated in this document are based on recombinant type III humanized collagen raw material. Other recombinant humanized collagen raw materials, if applicable, can be referred to Exam document.

2 Normative references

The contents of the following documents constitute the essential provisions of this document through normative references in the text. Among them, dated references For documents, only the version corresponding to the date is applicable to this document; for undated reference documents, the latest version (including all amendments) is applicable to this document. GB/T 16886.1 Biological evaluation of medical devices Part 1.Evaluation and testing in the risk management process YY/T 1849-2022 Recombinant Collagen Pharmacopoeia of the People's Republic of China

3 Terms and Definitions

YY/T 1849-2022 and the following terms and definitions apply to this document. 3.1 The full-length or partial amino acid sequence fragments encoded by human collagen-specific type genes prepared by DNA recombinant technology, or human collagen-containing A combination of functional fragments of collagen. 3.2 Human collagen types humancolagentypes Genetically, it can be divided into more than 20 different species, which differ in amino acid sequence, molecular assembly form or tissue distribution characteristics. Note. Different types of human collagen are generally named sequentially by Roman numerals, such as humanTypeⅠcolagen means human typeⅠcollagen. each type Human collagen is assembled by one or more collagen genes, for example, human type Ⅰ collagen is composed of human COL1A1 and COL1A2 genes coded assembly. 3.3 human collagen fragment humancolagenfragment It is an amino acid sequence fragment with a certain continuous length that can form a stable structure within the same amino acid sequence of human collagen.

4 Quality Control

Due to the different human collagen types and amino acid sequence fragments selected for recombinant humanized collagen, and the differences in expression systems, the amino acid sequence and physical and chemical properties are quite different. Used as raw materials for medical devices, it is necessary to establish a suitable method for quality control of products between different batches.

Tips & Frequently Asked Questions:

Question 1: How long will the true-PDF of YY/T 1888-2023_English be delivered?

Answer: Upon your order, we will start to translate YY/T 1888-2023_English as soon as possible, and keep you informed of the progress. The lead time is typically 2 ~ 4 working days. The lengthier the document the longer the lead time.

Question 2: Can I share the purchased PDF of YY/T 1888-2023_English with my colleagues?

Answer: Yes. The purchased PDF of YY/T 1888-2023_English will be deemed to be sold to your employer/organization who actually pays for it, including your colleagues and your employer's intranet.

Question 3: Does the price include tax/VAT?

Answer: Yes. Our tax invoice, downloaded/delivered in 9 seconds, includes all tax/VAT and complies with 100+ countries' tax regulations (tax exempted in 100+ countries) -- See Avoidance of Double Taxation Agreements (DTAs): List of DTAs signed between Singapore and 100+ countries

Question 4: Do you accept my currency other than USD?

Answer: Yes. If you need your currency to be printed on the invoice, please write an email to [email protected]. In 2 working-hours, we will create a special link for you to pay in any currencies. Otherwise, follow the normal steps: Add to Cart -- Checkout -- Select your currency to pay.